Heparin-Induced Thrombocytopenia, Fifth Edition

Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians.

This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of heparin-induced thrombocytopenia. By identifying key signs and symptoms and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage critical circumstances, this is an essential resource for all clinicians and a ‘must’ for hematology consultants.

The fifth edition includes:

• Coverage of approved and novel pharmacotherapies, current dosing guidelines, and the advantages and limitations of alternative anticoagulants,
• Review of the immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies,
• Description of clinical features, differential diagnosis, scoring systems, and frequency of HIT in diverse clinical settings--including pediatric patients--and provides evidence-based guidelines for the recognition, treatment, and prevention of this disorder,
• Detailed actions that should and should not be taken after the identification of heparin-induced thrombocytopenia,
• Selection criteria from a variety of new treatment options, helping physicians determine which of these agents are safe and effective for their patients,
• A comprehensive overview of clinical and laboratory studies on heparin-induced thrombocytopenia.

1. History of Heparin-Induced Thrombocytopenia
2. Clinical Picture of Heparin-Induced Thrombocytopenia
3. Differential Diagnosis of Heparin-Induced Thrombocytopenia and Scoring Systems
4. Frequency of Heparin-Induced Thrombocytopenia
5. Nonimmune Heparin-Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia
6. Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia
7. Role of Sulfated Polysaccharides and other Polyanions in the Pathogenesis of Heparin-Induced Thrombocytopenia
8. Platelet and Leukocyte Fcγ Receptors in Heparin-Induced Thrombocytopenia
9. Cellular and Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia
10. Murine Models of Heparin-Induced Thrombocytopenia
11. Laboratory Testing for Heparin-Induced Thrombocytopenia
12. Treatment of Heparin-Induced Thrombocytopenia: An Overview
13. Argatroban Therapy in Heparin-Induced Thrombocytopenia
14. Recombinant Hirudin for the Treatment of Heparin-Induced Thrombocytopenia
15. Bivalirudin for the treatment of Heparin-Induced Thrombocytopenia
16. Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia
17. Fondaparinux and Other Emerging Anticoagulants to Treat Heparin-Induced Thrombocytopenia
18. Hemodialysis in HIT
19. Management of Intraoperative Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery
20. Heparin-Coated Intravascular Devices and Heparin-Induced Thrombocytopenia
21. Heparin-Induced Thrombocytopenia in Children